Ben Cravatt, Ph.D., is Professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease. Ben obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Ben joined the faculty at TSRI in 1997. He is co-founder of several biotechnology companies, including Activx Biosciences, Abide Therapeutics, Vividion Therapeutics, and Belharra Therapeutics.
Ben’s honors include the Eli Lilly Award in Biological Chemistry, the ASBMB Merck Award, AACR Award for Achievement in Chemistry in Cancer Research, the Wolf Prize in Chemistry, the Heinrich Wieland Prize, and memberships in the National Academies of Inventors, Medicine, and Sciences.